In a welcome move, Marsh & McLennan saw its Relative Strength Rating rise from 66 to 71 on Monday.
Can You Really Time The Stock Market?
IBD's proprietary rating identifies share price performance with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research reveals that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they begin their biggest climbs. See if Marsh & McLennan can continue to rebound and hit that benchmark.
Marsh & McLennan is working on a consolidation with a 248.00 entry. See if it can break out in heavy trade.
Marsh & McLennan posted 5% EPS growth last quarter. Sales rose 9%.
The company earns the No. 7 rank among its peers in the Insurance-Brokers industry group. Kingstone, Ryan Specialty Holdings and Gallagher are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
